Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel

Alice K Pau; Judith Aberg; Jason Baker; Pamela S Belperio; Craig Coopersmith; Page Crew; Birgit Grund; Roy M Gulick; Carly Harrison; Arthur Kim; H Clifford Lane; Henry Masur; Virginia Sheikh; Kanal Singh; Jinoos Yazdany; Pablo Tebas; National Institutes of Health COVID-19 Treatment Guidelines Panel

doi:10.7326/M20-6448

Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel

Ann Intern Med. 2021 Jan;174(1):93-95. doi: 10.7326/M20-6448. Epub 2020 Sep 25.

Authors

Alice K Pau¹, Judith Aberg², Jason Baker³, Pamela S Belperio⁴, Craig Coopersmith⁵, Page Crew¹, Birgit Grund⁶, Roy M Gulick⁷, Carly Harrison⁸, Arthur Kim⁹, H Clifford Lane¹, Henry Masur¹, Virginia Sheikh¹⁰, Kanal Singh¹, Jinoos Yazdany¹¹, Pablo Tebas¹²; National Institutes of Health COVID-19 Treatment Guidelines Panel

Collaborators

National Institutes of Health COVID-19 Treatment Guidelines Panel:
Roy M Gulick, H Clifford Lane, Henry Masur, Alice K Pau, Judith Aberg, Adaora Adimora, Jason Baker, Lisa Baumann Kreuzige, Roger Bedimo, Pamela S Belperio, Stephen V Cantrill, Ann C Collier, Craig Coopersmith, Eric Daar, Susan L Davis, Amy L Dzierba, Laura Evans, John J Gallagher, Rajesh Gandhi, David V Glidden, Birgit Grund, Erica J Hardy, Carl Hinkson, Brenna L Hughes, Steven Johnson, Marla J Keller, Arthur Kim, Jeffrey L Lennox, Mitchell M Levy, Gregory Martin, Susanna Naggie, Andrew T Pavia, Nitin Seam, Steven Q Simpson, Susan Swindells, Pablo Tebas, Phyllis Tien, Alpana A Waghmare, Kevin C Wilson, Jinoos Yazdany, Danielle M Campbell, Carly Harrison, Timothy Burgess, Joseph Francis, Virginia Sheikh, Timothy M Uyeki, Robert Walke, Martha C Nason, Kanal Singh, Page Crew, Safia Kuriakose, Andrea M Lerner

Affiliations

¹ National Institutes of Health, Bethesda, Maryland (A.K.P., P.C., H.C.L., H.M., K.S.).
² Icahn School of Medicine at Mount Sinai, New York, New York (J.A.).
³ Hennepin Healthcare/University of Minnesota, Minneapolis, Minnesota (J.B.).
⁴ Department of Veterans Affairs, Los Angeles, California (P.S.B.).
⁵ Emory University School of Medicine, Atlanta, Georgia (C.C.).
⁶ University of Minnesota, Minneapolis, Minnesota (B.G.).
⁷ Weill Cornell Medicine, New York, New York (R.M.G.).
⁸ LupusChat, New York, New York (C.H.).
⁹ Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts (A.K.).
¹⁰ U.S. Food and Drug Administration, Silver Spring, Maryland (V.S.).
¹¹ University of California, San Francisco, San Francisco, California (J.Y.).
¹² University of Pennsylvania, Philadelphia, Pennsylvania (P.T.).

Abstract

In the United States, the efficacy and safety of convalescent plasma for treating coronavirus disease 2019 (COVID-19) is currently being tested in randomized placebo-controlled clinical trials. Treatment of individual patients with COVID-19 with convalescent plasma outside such trials is also now permitted through U.S. Food and Drug Administration Emergency Use Authorization. Here, members of the National Institutes of Health COVID-19 Treatment Guidelines Panel provide their views regarding use of convalescent plasma for treating COVID-19.

Publication types

Practice Guideline

MeSH terms

COVID-19 / immunology*
COVID-19 / therapy*
COVID-19 Serotherapy
Humans
Immunization, Passive / methods
National Institutes of Health (U.S.)
Plasma / immunology*
SARS-CoV-2
United States

Grants and funding

T32 DA023356/DA/NIDA NIH HHS/United States